Cost-Effectiveness of Adding Carfilzomib to Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma From a US Perspective
Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2016.1194278
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 16, 2016
Authors
Publisher
Informa UK Limited